Tag: INFOSYS
-
Indian IT Sector Braces for Mixed Q3 Results Amid Modest Growth Prospects
As the Indian IT sector prepares for Q3 FY25, Tier 1 companies like TCS, Infosys, and HCL Tech are projected to show modest revenue growth, while Tier 2 firms such as Coforge may reveal stronger results. Operating margins are expected to improve slightly despite challenges. Key sectors like BFSI and TMT indicate rising demand, and…
-
IT Companies Prepare for Mixed Q3 Results with Tier 1 Firms Anticipating Modest Growth
The Indian IT services sector is preparing for a mixed Q3 FY25, with Tier 1 companies expected to report modest revenue growth, while Tier 2 firms like Coforge may demonstrate stronger performance. Improving operational practices and demand, particularly in BFSI and TMT, contribute to this outlook. Additionally, generative AI is emerging as a key growth…
-
Q3 FY25 Results Preview: Indian IT Sector’s Expected Performance Insights
The Indian IT sector is preparing for Q3 FY25 earnings, with TCS leading on January 9. Analysts expect mild growth in major players, but tier-2 firms may outperform. Revenue results may be influenced by seasonal furloughs and macroeconomic factors, with forecasts indicating stable margins despite wage hikes. The Indian IT sector is poised for earnings…
-
Generative AI Threatens Pricing and Employment in India’s IT Services Industry
Generative AI aims to transform India’s $254 billion IT services sector, with anticipated pricing pressure on support and maintenance contracts starting next year. The ADM and BPO segments, which compose 40% of industry revenues, are under threat due to AI’s capability to automate tasks. Major firms like TCS and Infosys may face challenges as contract…
-
US Elections 2024: Impact on Stocks as Trump Leads Over Harris
As Donald Trump leads early in three states over Kamala Harris, stocks in the IT and pharmaceutical sectors are in focus. Trump’s prior executive actions on immigration and upcoming healthcare policies may significantly affect these industries. Both parties are aiming to adjust drug pricing, which could create divergent outcomes for pharmaceutical companies. Overall, upcoming US…